Mark D. Alexander
{ Bio Portrait }


TEL NY 212.728.2237
TEL2 CT 860.275.8130
New York
Download V-Card
Print PDF

With more than 20 years at Axinn, Mark Alexander provides sophisticated and practical counsel on complex antitrust issues. His practice focuses on antitrust merger clearance, litigation and counseling.

Mark has handled antitrust aspects of dozens of mergers and acquisitions in a host of industries, including life sciences, wireless and wireline telecommunications, pharmaceuticals, medical devices, oil & gas, oil exploration services, consumer products, mining and minerals, insurance brokerages and business services. His antitrust litigation experience has included representing a corporate plaintiff in a challenge to attempted monopolization in the chemicals industry under Section 2 of the Sherman Act, defending a media merger from a private party challenge under Section 7 of the Clayton Act and defending advertising industry trade group activities from a challenge under Section 1 of the Sherman Act.

Mark has litigated and arbitrated a wide range of complex commercial disputes before courts and arbitrators across the United States. He has handled several disputes under the Uniform Commercial Code concerning supply agreements in the chemicals industry. Mark’s other commercial litigation and arbitration experience includes a contract dispute among international investment consortium members, a dispute involving oil and gas exploration rights and an arbitration involving specialized software for the higher education industry.

Prior to joining the firm, Mark practiced in the New York and London offices of Sullivan & Cromwell LLP.

More » « Less

Professional Activities

  • American Bar Association, Section of Antitrust Law
  • Connecticut Bar Association
  • Tennessee Bar Association



  • Thermo Fisher Scientific in its $13.6 billion acquisition of Life Technologies
  • Thermo Fisher Scientific in its $12.5 billion tender offer for QIAGEN N.V.
  • Johnson Controls in the $2 billion sale of its Scott Safety business to 3M
  • Thermo Fisher Scientific in its $7.2 billion acquisition of Patheon N.V.
  • McKesson in its $1.4 billion acquisition of CoverMyMeds LLC
  • Ball Corporation in its $6.85 billion acquisition of Rexam PLC
  • Thermo Fisher Scientific in its $4.2 billion acquisition of FEI Company
  • Charles River Laboratories International, Inc. in its $585 million acquisition of WIL Research
  • Thermo Fisher Scientific in its $1.3 billion acquisition of Affymetrix
  • SunGard Higher Education in its $1.77 billion sale of SunGard Higher Education to Datatel
  • Cingular in its $41 billion acquisition of AT&T Wireless


  • Obtained a victory in the U.S. Court of Appeals for the Fourth Circuit that helped Watson Laboratories (now Actavis), speed its generic version of Celebrex® to market

  • Successfully briefed and argued an appeal on behalf of national insurance broker Brown & Brown, winning unanimous affirmance in the Connecticut Supreme Court of summary judgment on all claims brought by Blumberg Associates Worldwide

  • Secured summary judgment on behalf of Watson Laboratories, Inc. in litigation against the U.S. Food and Drug Administration in the U.S. District Court for the District of Columbia


  • Best Lawyers in America (2018 – 2024)
  • Symposium Editor, Cornell Law Review. Honors:  American Jurisprudence Awards in Civil Procedure, Criminal Law and Torts



  • JD, cum laude – Cornell Law School (1992)
  • BA – Indiana University (1989)


  • Connecticut
  • New York
  • Tennessee
  • US Court of Appeals for the Fourth Circuit
  • US Court of Appeals for the Seventh Circuit
  • US District Court District of Connecticut
  • US District Court Southern District of New York

By using the Axinn, Veltrop & Harkrider LLP website with cookies enabled on your browser, you agree to our use of cookies during your browsing experience. Learn more about our privacy policy.